Vaxxilon AG

Vaxxilon AG is dedicated to the discovery, development and commercialization of innovative synthetic carbohydrate vaccines to prevent, first and foremost, bacterial infections. Vaxxilon has licensed multiple preclinical vaccine candidates to target pathogens for which there are no approved vaccines, or for which existing vaccines do not fully meet medical needs. Vaxxilon was created in 2015 by Actelion Ltd and the Max Planck Society. The company is based on the scientific insights and innovation of Professors Peter Seeberger of the Max Planck Institute of Colloids and Interfaces and Gennaro de Libero of the University Hospital of Basel.